We are improving our search experience. To check which content you have full access to, or for advanced search, go back to the old search.

Search

Please fill in this field.

Search Results

Showing 81-100 of 10,000 results
  1. Highly immunosuppressive myeloid cells correlate with early relapse after allogeneic stem cell transplantation

    Background

    Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only curative treatment for myeloid malignancies such as some acute...

    Anne-Béatrice Notarantonio, Allan Bertrand, ... Maud D’Aveni in Experimental Hematology & Oncology
    Article Open access 11 May 2024
  2. Sporadic and Familial Acute Myeloid Leukemia with CEBPA Mutations

    Purpose of Review

    CCAAT enhancer binding protein A ( CEBPA ) gene mutation is one of the common genetic alterations in acute myeloid leukemia (AML),...

    Ji Yuan, Rong He, Hassan B. Alkhateeb in Current Hematologic Malignancy Reports
    Article Open access 01 June 2023
  3. Multiple machine-learning tools identifying prognostic biomarkers for acute Myeloid Leukemia

    Background

    Acute Myeloid Leukemia (AML) generally has a relatively low survival rate after treatment. There is an urgent need to find new biomarkers...

    Yu**g Cheng, **n Yang, ... Chan Zhang in BMC Medical Informatics and Decision Making
    Article Open access 02 January 2024
  4. Allogeneic stem cell transplantation for patients with acute myeloid leukemia (AML) in second complete remission (CR2) transplanted from unrelated donors with post-transplant cyclophosphamide (PTCy). A study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

    Post-transplant cyclophosphamide (PTCy) is being increasingly used as graft-versus-host disease (GVHD) prophylaxis post allogeneic hematopoietic stem...

    Arnon Nagler, Myriam Labopin, ... Mohamad Mohty in Bone Marrow Transplantation
    Article 23 February 2023
  5. p200CUX1-regulated BMP8B inhibits the progression of acute myeloid leukemia via the MAPK signaling pathway

    The full-length p200CUX1 protein encoded by the homology frame CUT-like protein (CUX1) plays an important role in tumors as a pro-oncogene or...

    Meng Wang, Liang Zhong, ... Beizhong Liu in Medical Oncology
    Article 31 May 2024
  6. Develo** Strategies to Improve the Efficacy of CAR-T Therapy for Acute Myeloid Leukemia

    Acute myeloid leukemia (AML) is a fatal blood malignancy. With the development of immunotherapy, particularly chimeric antigen receptor T cells...

    Shu**g Guo, Xue** Gao, ... Ming Feng Zhao in Current Treatment Options in Oncology
    Article 23 October 2023
  7. Should anti-thymocyte globulin be added in post-transplant cyclophosphamide based matched unrelated donor peripheral blood stem cell transplantation for acute myeloid leukemia? A study on behalf of the Acute Leukemia Working Party of the EBMT

    In this registry-based study which includes acute myeloid leukemia patients who underwent a matched unrelated donor allogeneic peripheral-blood stem...

    Alexandros Spyridonidis, Myriam Labopin, ... Mohamad Mohty in Bone Marrow Transplantation
    Article 07 September 2022
  8. Lycorine induces apoptosis of acute myeloid leukemia cells and inhibits triglyceride production via binding and targeting FABP5

    Acute myeloid leukemia (AML) is the most common hematopoietic malignancy with abnormal lipid metabolism. However, currently available information on...

    **nming Liang, Wenli Fu, ... Qifang Zhang in Annals of Hematology
    Article 21 March 2023
  9. Acute myeloid leukemia with rare recurring translocations—an overview of the entities included in the international consensus classification

    Two different systems exist for subclassification of acute myeloid leukemia (AML); the World Health Organization (WHO) Classification and the...

    Synne D. Rørvik, Synne Torkildsen, ... Tor Henrik Anderson Tvedt in Annals of Hematology
    Article Open access 06 March 2024
  10. Exploring the mechanism of fraxetin against acute myeloid leukemia through cell experiments and network pharmacology

    Objective

    Previous studies have shown that fraxetin has antitumor activity in a variety of tumors, but its role in acute myeloid leukemia (AML)...

    Tingting Fang, Lanqin Liu, Wenjun Liu in BMC Complementary Medicine and Therapies
    Article Open access 10 June 2024
  11. Prognostic factors and clinical outcomes in patients with relapsed acute leukemia after allogeneic hematopoietic stem cell transplantation

    Relapse is a significant barrier to allogeneic hematopoietic stem cell transplantation (allo-HSCT) success. To explore the prognosis of patients who...

    Yang Gao, Hengwei Wu, ... Yanmin Zhao in Bone Marrow Transplantation
    Article 29 April 2023
  12. Functional characterization of cooperating MGA mutations in RUNX1::RUNX1T1 acute myeloid leukemia

    MGA (Max-gene associated) is a dual-specificity transcription factor that negatively regulates MYC-target genes to inhibit proliferation and promote...

    Melvin E. Thomas III, Wenqing Qi, ... Jeffery M. Klco in Leukemia
    Article Open access 07 March 2024
  13. Update on Small Molecule Targeted Therapies for Acute Myeloid Leukemia

    The search for effective therapies for the highly heterogenous disease acute myeloid leukemia (AML) has remained elusive. While cytotoxic therapies...

    Jiasheng Wang, Benjamin Tomlinson, Hillard M. Lazarus in Current Treatment Options in Oncology
    Article 17 May 2023
  14. Inhibition of PI3K-AKT-mTOR pathway and modulation of histone deacetylase enzymes reduce the growth of acute myeloid leukemia cells

    One of the most widespread forms of blood cancer is known as acute myeloid leukemia (AML) which has an incidence of 80% with poor prognosis. Although...

    Merve Şansaçar, Helin Sağır, Emel Başak Gencer Akçok in Medical Oncology
    Article 26 December 2023
  15. Flow cytometric measurable residual disease in adult acute myeloid leukemia: a preliminary report from Eastern India

    Presence of measurable residual disease (MRD) in acute myeloid leukemia (AML) is considered to be an independent predictor of relapse and poorer...

    Neha Singh, Avinash Gupta, ... Anil Singh in Journal of Hematopathology
    Article 10 January 2023
  16. Auraptene-induced cytotoxic effects in acute myeloid leukemia cell lines

    Acute myeloid leukemia is one of the most commonly identified hematological malignancies with poor prognosis. This research was planned to identify...

    Majid Ghorbani, Mohammad Soukhtanloo, ... Mohammad Hadi Sadeghian in Medical Oncology
    Article 11 July 2023
  17. Identifying prognostic biomarker related to immune infiltration in acute myeloid leukemia

    The immune cells of tumor microenvironment (TME) constitute a vital element of the tumor tissue. There is increasing evidence for their clinical...

    Weixiang Lu, Guopan Yu, ... Dan Xu in Clinical and Experimental Medicine
    Article 10 August 2023
  18. Post-transplant cyclophosphamide and sirolimus based graft-versus-host disease prophylaxis after allogeneic stem cell transplantation for acute myeloid leukemia

    Post-transplant cyclophosphamide (PTCy) has emerged as a promising graft-versus-host disease (GvHD) prophylaxis in allogeneic hematopoietic stem cell...

    Lorenzo Lazzari, Aitana Balaguer-Roselló, ... Jaime Sanz in Bone Marrow Transplantation
    Article Open access 09 June 2022
  19. Survival advantage of treosulfan plus fludarabine (FT14) compared to busulfan plus fludarabine (FB4) in active acute myeloid leukemia post allogeneic transplantation: an analysis from the European Society for Blood and Marrow Transplantation (EBMT) Acute Leukemia Working Party (ALWP)

    We compared FT14 (fludarabine 150–160 mg/m 2 , treosulfan 42 g/m 2 ) versus FB4 (fludarabine 150–160 mg/m 2 , busulfan 12.8 mg/kg) in acute myeloid...

    Eleni Gavriilaki, Ioanna Sakellari, ... Mohamad Mohty in Bone Marrow Transplantation
    Article 07 July 2023
  20. Comparing Arsenic-Containing Qinghuang Powder and Low-Intensity Chemotherapy in Elderly Patients with Acute Myeloid Leukemia

    Objective

    To compare the clinical effect of arsenic-containing Qinghuang Powder (QHP) and low-intensity chemotherapy (LIC) in treatment of elderly...

    Yu-he Wu, Hai-yan **ao, ... **ao-mei Hu in Chinese Journal of Integrative Medicine
    Article 24 May 2023
Did you find what you were looking for? Share feedback.